inPractice® - Sofosbuvir/Velpatasvir/Voxilaprevir

Sofosbuvir/velpatasvir/voxilaprevir is approved for 12-week use in patients with compensated cirrhosis who either have genotype 1-6 HCV infection and were previously treated with an NS5A inhibitor–containing regimen or have genotype 1a or 3 HCV infection and were previously treated with sofosbuvir^{[FDA Sofosbuvir Velpatasvir Voxilaprevir]}
High SVR12 rates observed in phase III trials in patients with compensated cirrhosis and previous DAA experience
- POLARIS-1: SVR12 93% in patients with cirrhosis, genotype 1-6 HCV infection, and previous NS5A inhibitor experience^{[Bourlière 2017]}